Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Oliver Wyman Completes Acquisition of Huron’s Life Sciences Strategy Consulting Practice


Oliver Wyman, a global management consulting firm and a business of Marsh McLennan (NYSE: MMC), today completed the acquisition of Huron’s life sciences strategy consulting practice. Terms of the acquisition were not disclosed.

“Through this combination, we will continue our relentless pursuit of a better way in healthcare, partnering with pharmaceutical, biotechnology, and medical device companies. Our new colleagues bring the expertise needed to help life sciences companies tackle their most pressing strategic questions, including increasingly complex commercialization and access-related issues,” commented Sam Glick, Partner and Global Leader of Health and Life Sciences at Oliver Wyman.

“Combining the deep industry expertise of the Huron Life Sciences team with Oliver Wyman’s global scale and capabilities, will help us holistically address the challenges of the life sciences sector,” said John Westwood, Partner and Global Life Sciences Business Leader at Oliver Wyman and former Global Life Sciences Practice Leader at Huron. “Now as part of Oliver Wyman, we look forward to working side-by-side with our clients to help shape healthcare’s future.”

The acquisition advances Oliver Wyman’s leadership in life sciences strategy consulting, helping the firm deliver critical commercial strategy, marketing, pricing, market access, and R&D advice to a broader set of clients.

The acquisition also grows Oliver Wyman’s deep bench of talent, adding 80 professionals, including 12 partners, to its Health and Life Sciences practice. These senior professionals have longstanding relationships with many of the world’s top pharmaceutical, biotechnology, diagnostics, and medical device companies.

About Oliver Wyman
Oliver Wyman is a global leader in management consulting. With offices in 60 cities across 29 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm has more than 5,000 professionals around the world who work with clients to optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities. Oliver Wyman is a business of Marsh McLennan (NYSE: MMC). For more information, visit www.oliverwyman.com. Follow Oliver Wyman on Twitter @OliverWyman.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005721/en/

Marsh & McLennan Companies Inc. Aktie

184,95 €
-0,51 %
Die Marsh & McLennan Companies Inc. Aktie verzeichnet heute einen kleinen Rückgang um -0,51 %.
Mehr Buy- als Sell-Zahlen bei Marsh & McLennan Companies Inc. zeigen ein leicht positives Sentiment.
Ein unerwartetes negatives Potenzial von -0.51% für Marsh & McLennan Companies Inc., trotz eines niedrigeren Kursziels von 184 € als der aktuelle Kurs von 184.95 €.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare